Reversible memory loss in a mouse transgenic model of Alzheimer’s disease

Developments of a water-maze procedure for studying spatial learning in the rat

Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180

Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,506

Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431

Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298

Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease

Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 10×

Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?

Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989

Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858

Diminished Amyloid-β Burden in Tg2576 Mice Following a Prophylactic Oral Immunization with a Salmonella-Based Amyloid-β Derivative Vaccine

Boutajangout, A., Goñi, F., Knudsen, E., Schreiber, F., Asuni, A. A., Quartermain, D., Frangione, B., Chabalgoity, A., Wısnıewskı, T., & Sigurdsson, E. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1204 · Cited by 15

Conditionally inducible tau mice – designing a better mouse model of neurodegenerative diseases

Janus, C. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00375.x · Cited by 16

Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivomodel of Alzheimer’s disease

Löffler, T., Flunkert, S., Havas, D., Schweinzer, C., Uger, M. D., Windisch, M., Steyrer, E., & Hutter‐Paier, B. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-84 · Cited by 15

Nonviral DNA Vaccination Augments Microglial Phagocytosis of β-Amyloid Deposits as a Major Clearance Pathway in an Alzheimer Disease Mouse Model

Okura, Y., Kohyama, K., Park, I.-K., & Matsumoto, Y. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818b48db · Cited by 15

Recent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease

Alshamrani, M. (2023) · Antibodies · doi:10.3390/antib12020041 · Cited by 17

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?

Kayed, R., Castillo‐Carranza, D. L., & Guerrero‐Munoz, M. J. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s40131 · Cited by 16

A mimotope peptide of Aβ42 fibril-specific antibodies with Aβ42 fibrillation inhibitory activity induces anti-Aβ42 conformer antibody response by a displayed form on an M13 phage in mice

Tanaka, K., Nishimura, M., Yamaguchi, Y., Hashiguchi, S., Takiguchi, S., Yamaguchi, M., Tahara, H., Gotanda, T., Abe, R., Ito, Y., et al. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.04.010 · Cited by 14

Soluble Oligomers of the Amyloid β-Protein: Impair Synaptic Plasticity and Behavior

Selkoe, D. J. (2008) · Springer eBooks · doi:10.1007/978-3-540-76330-7_8 · Cited by 13

Drug Targets from Genetics: Alpha-Synuclein

Danzer, K. M., & McLean, P. J. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711797247867 · Cited by 13

Pre-amyloid oligomers budding:a metastatic mechanism of proteotoxicity

Bernini, F., Malferrari, D., Pignataro, M., Bortolotti, C. A., Rocco, G. D., Lancellotti, L., Brigatti, M. F., Kayed, R., Borsari, M., del Monte, F., et al. (2016) · Scientific Reports · doi:10.1038/srep35865 · Cited by 12

Immunolocalization of Kisspeptin Associated with Amyloid- β Deposits in the Pons of an Alzheimer’s Disease Patient

Chilumuri, A., Ashioti, M., Nercessian, A. N., & Milton, N. G. N. (2013) · Journal of Neurodegenerative Diseases · doi:10.1155/2013/879710 · Cited by 12

Disease Modifying Therapies for Alzheimer's Disease Targeting AβOligomers: Implications for Therapeutic Mechanisms

Matsubara, E., Takamura, A., Okamoto, Y., Oono, H., Nakata, T., Wakasaya, Y., Kawarabayashi, T., & Shoji, M. (2013) · BioMed Research International · doi:10.1155/2013/984041 · Cited by 12

Dietary supplementation with Allium hirtifolium and/or Astragalus hamosus improved memory and reduced neuro-inflammation in the rat model of Alzheimer’s disease

Bahaeddin, Z., Yans, A., Khodagholi, F., & Sahranavard, S. (2017) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2017-0585 · Cited by 12

Cytotoxic Intermediates in the Fibrillation Pathway: Aβ Oligomers in Alzheimer’s Disease as a Case Study

Klein, W. L. (2007) · Springer eBooks · doi:10.1007/0-387-25919-8_4 · Cited by 11

Nonhuman Amyloid Oligomer Epitope Reduces Alzheimer’s-Like Neuropathology in 3xTg-AD Transgenic Mice

Rasool, S., Martínez‐Coria, H., Milton, S. C. F., & Glabe, C. G. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8478-7 · Cited by 10

Antibody therapy for Alzheimer’s disease

Morgan, D. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.1.53 · Cited by 10

Alzheimer’s disease: a molecular mechanism, new hypotheses, and therapeutic strategies

Plečkaitytė, M. (2010) · Medicina · doi:10.3390/medicina46010011 · Cited by 10

Immune-Directed Gene Therapeutic Development for Alzheimer’s, Prion, and Parkinson’s Diseases

Maguire‐Zeiss, K. A., & Federoff, H. J. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9133-3 · Cited by 9

Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus

Sohrab, S. S., Karim, S., Kamal, M. A., Abuzenadah, A. M., Chaudhary, A., Al-Qahtani, M. H., & Mirza, Z. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660158 · Cited by 9

Neurobiology of Alzheimer’s Disease

Wong, P. C., Savonenko, A. V., Li, T., & Price, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00046-8 · Cited by 9

Specific Binding of Alzheimer's Aβ Peptide Fibrils to Single-Walled Carbon Nanotubes

Stefansson, S., Knight, M., & Ahn, S. N. (2012) · Nanomaterials and Nanotechnology · doi:10.5772/54650 · Cited by 8

Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview

Lau, L., & Brodney, M. A. (2007) · Springer eBooks · doi:10.1007/7355_2007_017 · Cited by 8

Longitudinal Assessment of Cognitive Function in the Appswe/PS1dE9 Mouse Model of Alzheimer’s-Related Beta-Amyloidosis

Soto, P. L., Young, M. E., DiMarco, G. M., George, B. E., Melnikova, T., Savonenko, A. V., & Harris, B. N. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.03.010 · Cited by 9

Sugar distributions on gangliosides guide the formation and stability of amyloid-β oligomers

Saha, J., Ford, B. J., Wang, X., Boyd, S., Morgan, S. E., & Rangachari, V. (2023) · Biophysical Chemistry · doi:10.1016/j.bpc.2023.107073 · Cited by 6

Drug Development for Alzheimer's Disease: Recent Progress

Ji, W., & Ha, I. (2010) · Experimental Neurobiology · doi:10.5607/en.2010.19.3.120 · Cited by 7

Is glial heme oxygenase-1 suppression in neurodegenerative disorders permissive for neural repair?

Schipper, H. M. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.152371 · Cited by 7

Why Alzheimer’s is a Disease of Memory: Synaptic Targeting by Pathogenic Aβ Oligomers (ADDLs)

Klein, W. L., Felice, F. G. D., Lacor, P. N., Lambert, M. P., & Zhao, W.-Q. (2008) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-540-76330-7_9 · Cited by 7

Mouse models of Anti-Aβ immunotherapies

Pikus, P., Turner, R. S., & Rebeck, G. W. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00836-x · Cited by 6

Overview of Alzheimer's and Parkinson's diseases and the role of protein aggregation in these neurodegenerative diseases

Lelos, M. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00002-7 · Cited by 5

Oligomerization and toxicity of Aβ fusion proteins

Caine, J. M., Bharadwaj, P. R., Sankovich, S. E., Ciccotosto, G. D., Streltsov, V. A., & Varghese, J. N. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.05.029 · Cited by 6

Oral Immunization with Soybean Storage Protein Containing Amyloid-β 4–10 Prevents Spatial Learning Decline

Kawarabayashi, T., Terakawa, T., Takahashi, A., Hasegawa, H., Narita, S., Sato, K., Nakamura, T., Seino, Y., Hirohata, M., Baba, N., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190023 · Cited by 6

Cognitive Impairment in Transgenic Mouse Models of Amyloid Deposition

Morgan, D. (2006) · Frontiers in neuroscience · doi:10.1201/9781420004335.sec3 · Cited by 6

Non-cholinergic drug development for Alzheimer's disease

Yaari, R., Kumar, S., & Tariot, P. N. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.7.745 · Cited by 6

Multimodal photoacoustic microscopy and optical coherence tomography ocular biomarker imaging in Alzheimer's disease in mice

Zhai, T., Qian, W. P., Paulus, Y. M., Wang, X., & Zhang, W. (2024) · Biomedical Optics Express · doi:10.1364/boe.532042 · Cited by 5

Human iPSC‐Derived Mononuclear Phagocytes Improve Cognition and Neural Health across Multiple Mouse Models of Aging and Alzheimer's Disease

Moser, V. A., Dimas‐Harms, L. J., Lipman, R. M., Inzalaco, J., Bell, S., Alcantara, M., Valenzuela, E., Lawless, G. M., Kreimer, S. D., Parker, S. J., et al. (2025) · Advanced Science · doi:10.1002/advs.202417848 · Cited by 5

Targeting apolipoprotein E and N-terminal amyloid β-protein precursor interaction improves cognition and reduces amyloid pathology in Alzheimer’s mice

Sawmiller, D. R., Koyama, N., Fujiwara, M., Segawa, T., Maeda, M., & Mori, T. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104846 · Cited by 5

Cognitive Impairment in Transgenic Mouse Models of Amyloid Deposition

Levin, E. D., & Buccafusco, J. J. (2006) · CRC Press eBooks · doi:10.1201/9781420004335-15 · Cited by 5

Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice

Paganetti, P., Reichwald, J., Bleckmann, D., Abramowski, D., Ammaturo, D., Barske, C., Danner, S., Molinari, M., Müller, M. M., Papin, S., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.013 · Cited by 5

Emerging Therapeutic Strategies in Alzheimer's Disease

Chiba, T. (2013) · InTech eBooks · doi:10.5772/55293 · Cited by 5

Role of Alzheimer's disease models in designing and testing experimental therapeutics

Savonenko, A. V., Laird, F. M., Troncoso, J. C., Wong, P. C., & Price, D. L. (2005) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2005.11.006 · Cited by 5

β-Amyloid(1–42) induces a reduction in the parallel fiber responses of Purkinje cells: Possible involvement of pro-inflammatory processes

Arbez, N., Gautheron, V., Brugg, B., Mariani, J., & Rovira, C. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2007.05.007 · Cited by 5

Chapter 5.5 Transgenic mouse models of Alzheimer's disease and episodic-like memory

Borchelt, D., & Savonenko, A. V. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(08)00230-0 · Cited by 4

Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease

Steinitz, M. O. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.5.633 · Cited by 5

Molecular Aspects of Memory Dysfunction in Alzheimer’s Disease

Chin, J., Roberson, E. D., & Mucke, L. (2008) · Elsevier eBooks · doi:10.1016/b978-012370509-9.00015-2 · Cited by 5

Impact and Interrelationships of Striatal Proteins, EPHB2, OPRM1, and PER2 on Mild Cognitive Impairment

Campomayor, N. B., Kim, H. J., Lee, H. J., Sayson, L. V., Ortiz, D. M., Cho, E., Kim, D., Jeon, S. J., Kim, B.-N., Cheong, J. H., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04334-x · Cited by 3

Centella asiatica improves cognitive function and alters the hippocampal metabolome of aged Tg2576 and wild-type mice

Matthews, D. G., Khorani, M., Bobe, G., Caruso, M. A., Magaña, A. A., Gray, N. E., Quinn, J. F., Stevens, J. F., Maier, C. S., & Soumyanath, A. (2024) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241296740 · Cited by 4

Alzheimer's Disease: Clinical Features, Neuropathologies and Biochemical Abnormalities, Genetics, Models, and Experimental Therapeutics

Price, D. L., Borchelt, D., & Wong, P. C. (2005) · Elsevier eBooks · doi:10.1016/b978-012738903-5/50028-x · Cited by 3

Symptomatic and preclinical Alzheimer’s disease: Neuropathology and imaging

Thal, D. R. (2016) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2016.01.001 · Cited by 3

APP-Based Transgenic Models: The Tg2576 Model

Deacon, R. M. J. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_19 · Cited by 3

Actions of Bioactive Phytochemicals in Cell Function and Alzheimer’s Disease Pathology

Hartman, R. E. (2009) · Oxidative stress and disease · doi:10.1201/9781420073522.ch16 · Cited by 3

Neurodegenerative Diseases as Protein Folding Disorders

Baker, J. D., Webster, J. M., Shelton, L. B., Koren, J., Uversky, V. N., Blair, L. J., & Dickey, C. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00009-2 · Cited by 3

Immunotherapeutic Approaches to Alzheimer’s Disease

Karkos, J. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_15 · Cited by 4

Cognitive Impairment in Transgenic Aβ and Tau Models of Alzheimer’s Disease

Ashe, K. H. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_5 · Cited by 3

Clinical approach and pathological cascabe of dementia

Shoji, M. (2008) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.48.467 · Cited by 3

Neurodegenerative Diseases and Dementia

Janus, C., & Welzl, H. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3777-6_6 · Cited by 2

Immunotherapy for Alzheimer’s Disease

Ikezu, T. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_45 · Cited by 2

New Developments in the Treatment of Alzheimer’s Disease

Rabins, P. V., Graff‐Radford, N. R., Small, G. W., & Yaari, R. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8002ah1c · Cited by 3

Cognition in Rodents

Janus, C., Galsworthy, M. J., Wolfer, D. P., & Welzl, H. (2009) · Springer eBooks · doi:10.1007/978-0-387-76727-7_11 · Cited by 2

Preclinical models of Alzheimer’s disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy

Vasconcelos, B., Bird, M., Stancu, I., Terwel, D., & Dewachter, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00006-3 · Cited by 2

ANTI-AMYLOID-β IMMUNOTHERAPY AS A TREATMENT FOR ALZHEIMER'S DISEASE

Cirrito, J. R., & Holtzman, D. M. (2008) · Elsevier eBooks · doi:10.1016/b978-012373994-0.50014-2 · Cited by 2

Type 2 Diabetes and Alzheimer's Disease: From Common Pathologies to Potential New Therapeutics

Levy, D. E. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100418 · Cited by 2

DNA Vaccination May Open Up a New Avenue for Treatment of Alzheimer Disease

Tsuji, S. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1832 · Cited by 2

Immunotherapy of Alzheimer’s Disease

Tondo, G., Marchi, F. D., Anselmi, M., & Comi, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_51 · Cited by 1

Progress and challenges in drug delivery for the treatment of Alzheimer’s disease

Haghighi, F. H., Xie, J., Ebert, E., & Siahaan, T. J. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2663114 · Cited by 1

Place cell physiology in a transgenic mouse model of Alzheimer's disease

Yi, M. (2009) · Cited by 1

Molecular Mechanism Underlying Aβ Immunotherapy: Implications for the Toxic Action of Aβ Oligomers

Matsubara, E. (2013) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.s2-001 · Cited by 1

Pathology of synapses in neurological diseases

Schwarzman, A. L., & Sarantseva, S. V. (2014) · Biology Bulletin Reviews · doi:10.1134/s2079086415020085 · Cited by 1

Strategies for Inhibiting Protein Aggregation: Therapeutic Approaches to Protein-Aggregation Diseases

Lanning, J. D., & Meredith, S. C. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_14 · Cited by 1

A Naturally Occurring β-Secretase Modulator, Tannic Acid, Improves Behavioral Impairment and Mitigates Alzheimer-Like Pathology

Mori, T., & Town, T. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407824-6.00100-2 · Cited by 1

Neurodegenerative disorders

Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.030 · Cited by 1

Application to Gene Therapy and Vaccination

Su, L., Bowers, W. J., Janelsins, M. C., & Federoff, H. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_52 · Cited by 1

Molecular Mechanisms of Synaptic Plasticity and Memory and Their Dysfunction in Alzheimer's Disease ☆

Stephens, G. S., You, J. C., Fu, C.-H., & Chin, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21126-7 · Cited by 1

Models of Alzheimer’s Disease

Chen, M., Kretzschmar, D., Verdile, G., & Lardelli, M. T. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00025-7 · Cited by 2

Frontiers in Clinical Drug Research - Alzheimer Disorders

Atta-ur-rahman, Mavoungou, C., Zimmerman, K. S., Wright, J., Harding, J., Cavallaro, R., Fuso, A., Yoshiyama, Y., Asija, Z., Clifford, A., et al. (2015) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/97816810806801150301 · Cited by 1

Mouse Models of Alzheimer’s Disease

German, D. C. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_16 · Cited by 1

The Contribution of Transgenic Models to the Understanding of Alzheimer's Disease Progression and Therapeutic Development

Chabrier, M. A., Neely, K. M., Castello, N. A., & LaFerla, F. M. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781849731843-00001 · Cited by 1

Current and Future Therapies for Alzheimer Disease

Chakrabarty, P., Das, P., & Golde, T. E. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch34 · Cited by 1

Gene Therapy and Vaccination

Bowers, W. J., Janelsins, M. C., & Federoff, H. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-72573-4_48 · Cited by 1

Treatment of Dementia

Singh, J., Sabbagh, M. N., Nair, A. K., Grundman, M., Kinney, G. G., Yuen, E., & Black, R. S. (2014) · Wiley eBooks · doi:10.1002/9781118730676.ch23 · Cited by 1

Etude des effets des peptides amyloïdes : du fonctionnement de la synapse aux modifications du cytosquelette dans l'apoptose neuronale.

Arbez, N. (2005) · HAL · Cited by 1

Targeting Early Stages of Alzheimer’s Disease in a Transgenic Model

Lord, A. (2009) · KTH Publication Database DiVA (KTH Royal Institute of Technology)

The Rationale for an Immunological Approach to Alzheimer's Therapeutics

Morgan, D. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_9

Effects of A-beta immunotherapy and Omega-3 fatty acid administration in Alzheimer's transgenic mice

Jensen, M. (2006)

Approaches to Amyloid Therapies for the Treatment of Alzheimer's Disease

Robichaud, A. J., Kim, J., & Jacobsen, J. S. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc249

Animal Models to Study the Biology of Amyloid‐β Protein Misfolding in Alzheimer Disease

Ashe, K. H. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch11

Effects of Adoptive Transfer of Beta-Amyloid Sensitive Immune Cells in a Mouse Model for Alzheimer’s Disease

Shippy, D. C. (2005) · Digital Commons - University of South Florida (University of South Florida)

Neural stem cell biology and neurogenesis in mouse models of aging and Alzheimer's disease

Ermini, F. (2006) · edoc (University of Basel) · doi:10.5451/unibas-003819315

Characterising transgenic APP mutation mouse models of amyloid pathology for use in preclinical immunotherapy

Hvoslef‐Eide, M. (2012) · ORCA Online Research @Cardiff (Cardiff University)

β-secretase: Physiological Role and Target Validation

Laird, F. M., Farah, M. H., Lee, H., Savonenko, A. V., Price, D. L., & Wong, P. C. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_4

Physico-chemical characterization of beta-amyloid oligomers and study of their function in biological processes at molecular level

Simon, D. (2011) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.1292

The action of xanomeline on human muscarinic receptors expressed in Chinese hamster ovary cells

Noetzel, M. J. (2009) · University of Minnesota Digital Conservancy (University of Minnesota)

Efecto del beta Amiloide (25-35) sobre la respuesta inhibitoria mediada por canales Girk en la sinapsis fimbria-CA3 del hipocampo

Nava-Mesa, M. O. (2011) · doi:10.14201/gredos.115640

The interaction between the neural cell adhesion molecule L1 and β-amyloid peptide : potential relevance in Alzheimer’s disease

Djogo, N. (2013)

Antibody-MediatedClearanceofAmyloid-Peptidefrom CerebralAmyloidAngiopathyRevealedbyQuantitative InVivoImaging

Prada, C. M., Greenberg, S. M., & Bacskai, B. J. (2007)

DivideandDie:CellCycleEventsasTriggersofNerve CellDeath

Herrup, K. (2004)

Immunotherapeutic Approaches for Alzheimer’s Disease

Bowers, W. J., & Federoff, H. J. (2006) · CRC Press eBooks · doi:10.3109/9781420016390-12

Unravelling the genetic components of late onset Alzheimer's disease.

Hamilton, G. (2005) · OpenGrey (Institut de l'Information Scientifique et Technique)

In Vitro and In Vivo Studies on Antibodies - N-terminally Truncated Abeta in the 5XFAD Mouse Model

Richard, B. C. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5098

Microglia phenotypes in aging-associated diseases

Yin, Z. (2017) · University of Groningen research database (University of Groningen / Centre for Information Technology)

Robotic Single Cell Manipulation for Biological and Clinical Applications

Leung, C. H. C. (2011) · TSpace (University of Toronto)

Brief Communication Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer’s Disease

Kotilinek, L., Bacskai, B. B., Westerman, M. A., Kawarabayashi, T., Younkin, L. H., Hyman, B. T., Younkin, S., & Ashe, K. H. (2002)

The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease

Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L. H., Carlson, G. A., Younkin, S. G., & Ashe, K. H. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01858.2002 · Cited by 731

S5–03–03: A specific amyloid–β assembly in the brain impairs memory

Ashe, K. H. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.364

Molecular basis of memory loss in the Tg2576 mouse model of Alzheimer's disease

Ashe, K. H. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s314 · Cited by 11

Plaque-bearing mice with reduced levels of oligomeric amyloid-β assemblies have intact memory function

Lesné, S., Kotilinek, L., & Ashe, K. H. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.10.054 · Cited by 159